Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2024-05-28 Earnings Release
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Earnings Release Classification · 95% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' scheduled for publication on 28/05/2024. It mentions 'BioLineRx Reports First Quarter 2024 Financial Results' and attaches a file named 'FORM_6-K_28-May-2024_isa.pdf'. A Form 6-K is typically used by foreign private issuers to report material information to the SEC, often coinciding with earnings releases or interim reports. Since this document announces the results for the First Quarter (an interim period) and is very short (2027 chars) primarily serving as an announcement linking to the actual report, it fits the definition of an Interim/Quarterly Report (IR) or potentially an Earnings Release (ER). Given the context of 'First Quarter 2024 Financial Results' and the reference to a periodic report, 'IR' (Interim / Quarterly Report) is the most appropriate classification for the underlying content being announced. However, applying the 'MENU VS MEAL' rule, since this document is an announcement stating the report is attached/published, it is best classified as a Report Publication Announcement (RPA) or potentially an Earnings Release (ER) if the attached document is the primary ER. Since the text explicitly mentions 'First Quarter 2024 Financial Results' and is filed with the ISA/TASE, it strongly suggests an earnings announcement. Given the options, 'ER' (Earnings Release) is often used for the initial announcement of quarterly results, even if the full details are in an attachment (like a 6-K). If the attached document is the full interim report, IR would fit. Given the focus on 'First Quarter 2024 Financial Results', ER is a strong candidate, but IR covers comprehensive interim reports. Since the document is an announcement of results, ER is slightly more specific than RPA, but IR covers the comprehensive nature of a quarterly report. Let's re-evaluate based on the content: It announces the results of the First Quarter. This aligns best with 'ER' (Earnings Release) or 'IR' (Interim Report). Since it's announcing the results, ER is often the immediate filing. I will classify it as ER, as it is the announcement of the quarterly financial results. Q1 2024
2024-05-28 English
Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Regulatory Filings Classification · 97% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' as a 'REPORT OF FOREIGN PRIVATE ISSUER'. Form 6-K is used by foreign private issuers to report material information that they are required to disclose to their home country's securities regulator or stock exchange, or that they make public in their home country. This type of filing is generally used for current reports that do not fit neatly into the periodic reporting structure (like 10-K or 10-Q). The content is a press release announcing clinical trial data presentation at the ASCO Annual Meeting. Since Form 6-K is a general current report for foreign issuers and doesn't map directly to the specific categories like ER, CT, or IP, the most appropriate general regulatory/miscellaneous category is 'Regulatory Filings' (RNS), as it serves as the catch-all for required SEC filings that aren't the primary periodic reports or specific event filings listed.
2024-05-24 English
Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting*' and references a PDF file. This structure—a brief announcement stating that a more detailed report or document is attached or published—fits the definition of a Report Publication Announcement (RPA). Although it contains specific clinical trial news, the primary function of this filing, given its brevity and reference to an attached document, is to announce the publication of that information, making RPA the most accurate classification based on the provided rules (Rule 2: MENU VS MEAL).
2024-05-24 English
6-K
Regulatory Filings
2024-05-24 English
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings Classification · 95% confidence The document explicitly identifies itself as a "FORM 6-K" filed with the "SECURITIES AND EXCHANGE COMMISSION". Form 6-K is the standard filing for Foreign Private Issuers to report material information that is required to be publicly disclosed in their home country or stock exchange, or that is distributed to their shareholders. The content discusses a notification received from Nasdaq regarding minimum bid price compliance, which is material information. While the content is an announcement (press release attached as Exhibit 1), the primary document structure is the SEC Form 6-K wrapper itself. Since there is no specific code for Form 6-K, and it is a mandatory regulatory filing that doesn't fit the specific definitions like 10-K (Annual Report), ER (Earnings Release), or DIV (Dividend Notice), the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as a fallback for miscellaneous SEC filings not covered by other specific codes. The document length (9004 chars) is substantial enough that it is the filing itself, not just a brief announcement of a filing (which would lean towards RPA).
2024-05-19 English
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings Classification · 98% confidence The document is a very short filing (1874 characters) that explicitly states it is an 'Immediate Report' under Israeli regulations and announces that an attachment, 'FORM_6-K_19-May-2024_isa.pdf', contains the full information regarding the 'Nasdaq Minimum Bid Price Notification'. This structure—a brief announcement pointing to an attached document—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), according to the 'MENU VS MEAL' rule. Since the content is a specific regulatory notification (related to Nasdaq compliance, which is a type of regulatory event), and it is not a standard comprehensive report like 10-K or IR, the most appropriate classification is RNS, as it is a general regulatory announcement that doesn't fit the other specific categories like DIV, DIRS, or ER. The presence of the ISA and TASE headers confirms its regulatory nature.
2024-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.